Target intelligence / Profile preview

Threonine and Tyrosine Kinase (None)

Target
None
Molecular classification
Enzyme, Receptor, Dual-specificity kinase
01

Overview

Most "protein kinases" are enzymes transferring phosphate groups from ATP to specific amino acids (serine, threonine, tyrosine) on protein substrates, regulating activity in key pathways such as signal transduction, cell division, and differentiation. "Tyrosine kinases" specifically phosphorylate tyrosine residues, while "serine/threonine kinases" act on serine and threonine. Some kinases, known as "dual-specificity kinases" (e.g., MAP kinase kinases/MEKs), can phosphorylate both. Aberrant kinase activity is implicated in multiple diseases, notably cancer and autoimmunity, making them major pharmacological targets. The term "Threonine and Tyrosine Kinase" does not accurately refer to a unique canonical target; relevant canonical targets should be "Tyrosine kinase," "Serine/threonine kinase," or precise dual-specificity kinases such as "Mitogen-activated protein kinase kinase (MEK)".

Other names
Tyrosine kinaseSerine/threonine kinaseDual-specificity kinaseProtein kinase
02

Mechanism of action

Competitive inhibition of ATP-binding site (for many TKIs); Allosteric inhibition; Covalent inhibition; Type I–V inhibitor classes based on binding site and mechanism

03

Biological functions

Signal transductionCell cycle regulationCell proliferationApoptosisImmune regulationGene expression regulation
04

Disease associations

CancerAutoimmune diseasesFibrosisInflammatory diseasesNeurodegenerationCardiovascular disease
05

Safety considerations

Off-target effects, toxicityImmunosuppressionIncreased infection risk (e.g., herpes zoster with TYK2 inhibitor)Cardiotoxicity, cytopenias, liver toxicity (depending on the inhibitor)
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Overexpression or activation mutations of specific kinases (e.g., BCR-ABL for imatinib response in CML, EGFR mutations, TYK2 loss-of-function variants for reduced autoimmunity risk)

Beyond the preview

Go deeper on Threonine and Tyrosine Kinase (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Threonine and Tyrosine Kinase (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call